Bank of America spends over $250 million annually on GLP-1 weight-loss drugs
Bank of America is allocating more than $250 million each year to cover GLP-1 medications for its 210,000-plus staff, viewing the expense as a health benefit.
Bank of America is spending in excess of $250 million each year on GLP-1 weight-loss and diabetes medications for its workforce of more than 210,000 employees, according to CEO Brian Moynihan. He framed the spending as a worthwhile component of the bank’s roughly $2 billion annual health-care budget, citing short- and long-term health gains, including a reduced likelihood of heart disease. Moynihan acknowledged that some staff might depart before reaping the drug’s benefits but argued the initiative remains justified.
The bank is actively seeking lower-cost sources, especially now that the treatment is offered as oral pills. A 2026 survey by the International Foundation of Employee Benefit Plans found only 36 % of firms cover GLP-1 costs, and some large employers such as PwC have recently halted coverage for weight-loss purposes. a journalist at one outlet has reported on the broader challenges employers face as demand for GLP-1 drugs rises.
Why it matters
The story shows how major employers are reshaping benefits to address costly new weight-loss drugs and their impact on workforce health.
In this story